|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
04-3536131
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(IRS Employer Identification No.)
|
45 First Avenue
|
|
Waltham, Massachusetts
|
02451
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Title of each class
|
Name of each exchange on which registered
|
Common Stock, $.001 par value
|
NASDAQ Capital Market
|
|
Item 1A.
|
Risk Factors.
|
|
Item 1B.
|
Unresolved Staff Comments.
|
|
Item 2.
|
Properties.
|
|
Item 3.
|
Legal Proceedings.
|
|
Item 4.
|
Mine Safety Disclosures.
|
|
|
|
|
PART II
|
||
|
|
|
Item 5.
|
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
|
|
Item 6.
|
Selected Financial Data.
|
|
Item 7.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
|
Item 7A.
|
Quantitative and Qualitative Disclosures About Market Risk.
|
|
Item 8.
|
Financial Statements and Supplementary Data.
|
|
Item 9.
|
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
|
|
Item 9A.
|
Controls and Procedures.
|
|
Item 9B.
|
Other Information.
|
|
|
|
|
PART III
|
||
|
|
|
Item 10.
|
Directors, Executive Officers and Corporate Governance.
|
|
Item 11.
|
Executive Compensation.
|
|
Item 12.
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
|
|
Item 13.
|
Certain Relationships and Related Transactions, and Director Independence.
|
|
Item 14.
|
Principal Accountant Fees and Services.
|
|
|
|
|
PART IV
|
||
|
|
|
Item 15.
|
Exhibits and Financial Statement Schedules.
|
|
Item 16.
|
Form 10-K Summary.
|
|
|
|
|
SIGNATURES
|
|
1.
|
Third-party laboratory verification.
The AVL California Technology Center, a long-standing research and technology partner with the international automotive industry, confirmed our results in their state-of-the-art dynamometer test cell, which was outfitted with sophisticated emissions measurement equipment.
|
2.
|
Verifying longevity and reliability in the field.
By equipping one of our 75 kW units, already operating at a customer location in Southern California with the Ultera
®
low-emissions technology and a device to continuously monitor emissions we verified longevity and reliability. The Ultera
®
low-emissions system operated successfully for more than 25,000 hours, approximately 3.5 years, and consistently complied with California’s stringent emission standards over the entire field testing period.
|
3.
|
Additional independent tests.
During the field test, two companies licensed in California to test emissions each verified our results at different times. The results from one of these tests, obtained in August 2011, enabled us to qualify for New Jersey’s fast-track permitting. Virtually every state nationwide requires some kind of permit related to local air quality, but New Jersey allows an exemption for systems such as ours that demonstrate superior emissions performance. This certification was granted in November 2011, and since then we have sold Ultera
®
low-emissions systems to customers in this territory.
|
•
|
commercial and industrial natural gas fueled engines from other manufacturers; and
|
•
|
natural gas and biogas powered vehicle fleets - such as municipal bus fleets
|
•
|
Provide power when a utility grid is not available or goes out of service;
|
•
|
Reduce the customer’s total cost of purchasing electricity and other fuel;
|
•
|
Reduce emissions of criteria pollutants (NOx and CO) to near-zero levels and cut the emission of greenhouse gases such as carbon dioxide;
|
•
|
Provide reliable on-site power generation, heating and cooling services; and
|
•
|
Control maintenance costs and ensure optimal peak equipment performance.
|
•
|
Sacramento Municipal Utility District has provided test sites for the Company since 2010.
|
•
|
Southern California Gas Company and San Diego Gas & Electric Company, each a Sempra Energy subsidiary have granted us research and development contracts since 2004.
|
•
|
Department of Energy’s Lawrence Berkeley National Laboratory, with which the Company has had research and development contracts since 2005, including ongoing Microgrid development work related to the InVerde.
|
•
|
Eastern Municipal Water District has co-sponsored demonstration projects to retrofit both a natural-gas powered municipal water pump engine and a biofuel powered pumping station engine with the Ultera low emissions technology since 2012.
|
•
|
Consortium for Electric Reliability Technology Solutions executed research and development contracts with the Company, and provided a test site to the Company since 2005.
|
•
|
California Energy Commission executed research and development contracts with the Company from 2004 until March 2013.
|
•
|
The AVL California Technology Center performed a support role in research and development contracts as well as internal research and development on our Ultera
®
emission control system from August 2009 to November 2011. Currently, this testing center's work on emissions from gasoline vehicles which began in January of 2016 continues for the Ultra Emissions products.
|
•
|
Propane Education & Research Council (PERC) executed research and development contracts with the Company for work related to developing Ultera low emissions control systems for the propane powered fork truck market.
|
•
|
The Southwest Research Institute (SWRI), a non-profit independent research center located in San Antonio, Texas, has been engaged by the Company to complete the next phase of research in the Ultera
®
automotive application. This effort will focus on evaluation of advanced catalyst formulations tailored to the Ultera
®
process.
|
•
|
9,470,126: "Assembly and method for reducing ammonia in exhaust of internal combustion engines." This patent, granted in October 2016, is related to the
Ultera
emission control system applicable to all of our products.
|
•
|
9,121,326: “Assembly and method for reducing nitrogen oxides, carbon monoxide and hydrocarbons in exhausts of internal combustion engines.” This patent, granted in September 2015, is related to the
Ultera
emission control system applicable to all of our products.
|
•
|
8,829,698: “Power generation systems.” This patent, granted in September 2014, is for a power generation system that includes an internal combustion engine configured to provide rotational mechanical energy.
|
•
|
8,578,704: “Assembly and method for reducing nitrogen oxides, carbon monoxide, and hydrocarbons in exhausts of internal combustion engines.” This patent, granted in November 2013, is for the
Ultera
emission control system applicable to all our products.
|
•
|
7,239,034: “Engine driven power inverter system with cogeneration.” This patent, granted in July 2007, pertains to the utilization of an engine-driven CHP module combined with an inverter and applies to our
InVerde
product specifically.
|
•
|
7,243,017: “Method for controlling internal combustion engine emissions.” This patent, granted in July 2007, applies to the specific algorithms used in our engine controller for metering fuel usage to obtain the correct combustion mixture and is technology used by most of our engines.
|
•
|
"Systems and methods for reducing emissions in exhaust of vehicles and producing electricity." This application, filed in November 2015 and published in March 2016, is related to the development of the
Ultera
emission control system for vehicle applications.
|
•
|
“Poison-Resistant Catalyst and Systems Containing Same.” This application, filed in March 2016, relates to treatment of exhaust generated by internal combustion engines, combustion turbines, and boilers, and more particularly to systems and method for treating exhausts containing one or more poisons, such as sulfur.
|
•
|
“Internal Combustion Engine Controller.” This application, filed in October 2015, relates to controllers and control circuits for controlling an internal combustion engine, including a gas fired internal combustion prime motor used for driving a generator for generating electrical power.
|
•
|
“Emissions Control Systems and Methods for Vehicles.” This application, filed in April 2016 relates to emissions control systems for vehicles.
|
•
|
"Assemblies and Methods for Reducing Particulate Matter, Hydrocarbons, and Gaseous Oxides from Internal Combustion Engine Exhaust." This application, filed in February 2017 relates to emissions controls system for vehicles.
|
•
|
"Dual Stage Internal Combustion Engine Aftertreatment System Using Exhaust Gas Intercooling and Charger-Driven Air Ejector." This application filed in February 2017 relates to emissions controls systems for vehicles.
|
•
|
Product safety certifications and interconnection requirements;
|
•
|
Air pollution regulations which govern the emissions allowed in engine exhaust;
|
•
|
State and federal incentives for CHP technology;
|
•
|
Various local building and permitting codes and third party certifications;
|
•
|
Electric utility pricing and related regulations; and
|
•
|
Federal versus state laws regarding the legalization of cannabis for medicinal and recreational use.
|
•
|
combining Tecogen’s and ADGE’s businesses in a manner that permits Tecogen to achieve the synergies anticipated to result from the transaction, the failure of which would result in the anticipated benefits of the transaction not being realized in the time frame currently anticipated or at all;
|
•
|
maintaining existing agreements with customers, distributors, and vendors and avoiding delays in entering into new agreements with prospective customers, distributors, and vendors; and
|
•
|
addressing possible differences in corporate cultures and management philosophies.
|
•
|
results and timing of our product development;
|
•
|
results of the development of our competitors’ products;
|
•
|
regulatory actions with respect to our products or our competitors’ products;
|
•
|
actual or anticipated fluctuations in our financial condition and operating results;
|
•
|
actual or anticipated changes in our growth rate relative to our competitors;
|
•
|
actual or anticipated fluctuations in our competitors’ operating results or changes in their growth rate;
|
•
|
competition from existing products or new products that may emerge;
|
•
|
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;
|
•
|
issuance of new or updated research or reports by securities analysts;
|
•
|
fluctuations in the valuation of companies perceived by investors to be comparable to us;
|
•
|
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
|
•
|
additions or departures of key management or personnel;
|
•
|
disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain, maintain, defend or enforce proprietary rights relating to our products and technologies;
|
•
|
announcement or expectation of additional financing efforts;
|
•
|
sales of our Common Stock by us, our insiders, or our other stockholders; and
|
•
|
general economic and market conditions.
|
•
|
have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;
|
•
|
comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);
|
•
|
submit certain executive compensation matters to shareholder non-binding advisory votes;
|
•
|
submit for shareholder approval golden parachute payments not previously approved; and
|
•
|
disclose certain executive compensation related items such as the correlation between executive compensation and financial performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation, when such disclosure requirements are adopted.
|
Year Ended December 31, 2017
|
|
High
|
|
Low
|
||||
1st Quarter
|
|
$
|
4.35
|
|
|
$
|
3.50
|
|
2nd Quarter
|
|
4.17
|
|
|
3.04
|
|
||
3rd Quarter
|
|
3.50
|
|
|
2.95
|
|
||
4th Quarter
|
|
3.38
|
|
|
2.20
|
|
Year Ended December 31, 2016
|
|
High
|
|
Low
|
||||
1st Quarter
|
|
$
|
6.50
|
|
|
$
|
2.80
|
|
2nd Quarter
|
|
5.75
|
|
|
3.50
|
|
||
3rd Quarter
|
|
5.20
|
|
|
4.00
|
|
||
4th Quarter
|
|
4.80
|
|
|
3.75
|
|
|
Years ended December 31,
|
||||
|
2017
|
|
2016
|
||
Revenues
|
100.0
|
%
|
|
100.0
|
%
|
Cost of Sales
|
61.0
|
|
|
62.0
|
|
Gross Profit
|
39.0
|
|
|
38.0
|
|
General and administrative
|
28.7
|
|
|
32.6
|
|
Selling
|
6.8
|
|
|
6.7
|
|
Research and development
|
2.8
|
|
|
2.7
|
|
Income (loss) from operations
|
0.7
|
|
|
(4.1
|
)
|
Total other expense, net
|
(0.4
|
)
|
|
(0.7
|
)
|
Consolidated net income (loss)
|
0.3
|
|
|
(4.7
|
)
|
(Income) loss attributable to the noncontrolling interest
|
(0.2
|
)
|
|
0.3
|
|
Net income (loss) attributable to Tecogen Inc.
|
0.1
|
%
|
|
(4.5
|
)%
|
•
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles;
|
•
|
provide reasonable assurance that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.
|
(a)
|
Index to Financial Statements and Financial Statement Schedules
|
(b)
|
Exhibits
|
Exhibit Number
|
Description
|
|
2.1
|
||
2.2
|
||
3.1
|
||
3.2
|
||
4.1
|
||
4.3+
|
||
4.5
|
||
4.6
|
||
10.1+
*
|
||
10.7
|
||
10.8
|
||
10.13#
|
||
10.21
|
||
10.24
|
||
10.26
|
||
10.29
|
||
10.30
|
||
10.31
|
||
10.32
|
||
10.34
|
10.35
|
||
10.36
|
||
10.37
|
||
10.38
|
||
10.39
|
||
10.40+
|
||
10.41
|
||
10.42+
|
||
10.43
|
||
21.1*
|
||
23.1*
|
||
31.1*
|
||
31.2*
|
||
31.3*
|
||
32.1*
|
||
101.INS*
|
XBRL Instance Document
|
|
101.SCH*
|
XBRL Taxonomy Extension Schema
|
|
101.CAL*
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase
|
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
|
|
|
*
|
Filed herewith.
|
|
#
|
Confidential Treatment has been granted for portions of this document. The confidential portions were omitted and filed separately, on a confidential basis, with the Securities and Exchange Commission.
|
|
+
|
Management contract or compensatory plan or agreement.
|
|
TECOGEN INC.
|
|
|
(Registrant)
|
|
|
|
|
Dated: March 21, 2018
|
By:
|
/s/ John N. Hatsopoulos
|
|
Co-Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
Dated: March 21, 2018
|
By:
|
/s/ Benjamin M. Locke
|
|
Co-Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
Dated: March 21, 2018
|
By:
|
/s/ Bonnie J. Brown
|
|
Chief Accounting Officer, Treasurer and Secretary
|
|
|
(Chief Accounting Officer)
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Angelina M. Galiteva
|
|
Chairman of the Board
|
|
March 21, 2018
|
Angelina M. Galiteva
|
|
|
|
|
|
|
|
|
|
/s/ John N. Hatsopoulos
|
|
Director and Co-Chief Executive Officer
|
|
March 21, 2018
|
John N. Hatsopoulos
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Benjamin M. Locke
|
|
Co-Chief Executive Officer
|
|
March 21, 2018
|
Benjamin M. Locke
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Bonnie J. Brown
|
|
Chief Accounting Officer, Treasurer and Secretary
|
|
March 21, 2018
|
Bonnie J. Brown
|
|
(Chief Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Charles T. Maxwell
|
|
Director
|
|
March 21, 2018
|
Charles T. Maxwell
|
|
|
|
|
|
|
|
|
|
/s/ Ahmed F. Ghoniem
|
|
Director
|
|
March 21, 2018
|
Ahmed F. Ghoniem
|
|
|
|
|
|
|
|
|
|
/s/ Keith Davidson
|
|
Director
|
|
March 21, 2018
|
Keith Davidson
|
|
|
|
|
|
|
|
|
|
/s/ Deanna Petersen
|
|
Director
|
|
March 21, 2018
|
Deanna Petersen
|
|
|
|
|
|
2017
|
|
2016
|
||||
ASSETS
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
1,673,072
|
|
|
$
|
3,721,765
|
|
Accounts receivable, net
|
9,536,673
|
|
|
8,630,418
|
|
||
Unbilled revenue
|
3,963,133
|
|
|
2,269,645
|
|
||
Inventory, net
|
5,130,805
|
|
|
4,774,264
|
|
||
Due from related party
|
585,492
|
|
|
260,988
|
|
||
Prepaid and other current assets
|
771,526
|
|
|
401,876
|
|
||
Total current assets
|
21,660,701
|
|
|
20,058,956
|
|
||
Property, plant and equipment, net
|
12,265,711
|
|
|
517,143
|
|
||
Intangible assets, net
|
2,896,458
|
|
|
1,065,967
|
|
||
Goodwill
|
13,365,655
|
|
|
40,870
|
|
||
Other assets
|
482,551
|
|
|
2,058,425
|
|
||
TOTAL ASSETS
|
$
|
50,671,076
|
|
|
$
|
23,741,361
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
5,095,285
|
|
|
$
|
3,367,481
|
|
Accrued expenses
|
1,416,976
|
|
|
1,378,258
|
|
||
Deferred revenue
|
1,293,638
|
|
|
876,765
|
|
||
Loan due to related party
|
850,000
|
|
|
—
|
|
||
Interest payable, related party
|
52,265
|
|
|
—
|
|
||
Total current liabilities
|
8,708,164
|
|
|
5,622,504
|
|
||
Long-term liabilities:
|
|
|
|
|
|
||
Deferred revenue, net of current portion
|
538,100
|
|
|
459,275
|
|
||
Senior convertible promissory note, related party
|
—
|
|
|
3,148,509
|
|
||
Unfavorable contract liability, net
|
7,729,667
|
|
|
—
|
|
||
Total liabilities
|
16,975,931
|
|
|
9,230,288
|
|
||
|
|
|
|
||||
Commitments and contingencies (Note 10)
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
|
||
Tecogen Inc. stockholders’ equity:
|
|
|
|
|
|
||
Common stock, $0.001 par value; 100,000,000 shares authorized; 24,766,892 and 19,981,912 issued and outstanding at December 31, 2017 and 2016, respectively
|
24,767
|
|
|
19,982
|
|
||
Additional paid-in capital
|
56,176,330
|
|
|
37,334,773
|
|
||
Accumulated other comprehensive loss-investment securities
|
(165,317
|
)
|
|
—
|
|
||
Accumulated deficit
|
(22,796,246
|
)
|
|
(22,843,682
|
)
|
||
Total Tecogen Inc. stockholders’ equity
|
33,239,534
|
|
|
14,511,073
|
|
||
Noncontrolling interest
|
455,611
|
|
|
—
|
|
||
Total stockholders’ equity
|
33,695,145
|
|
|
14,511,073
|
|
||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
50,671,076
|
|
|
$
|
23,741,361
|
|
|
2017
|
|
2016
|
||||
Revenues
|
|
|
|
|
|
||
Products
|
$
|
12,991,283
|
|
|
$
|
10,722,285
|
|
Services
|
16,377,443
|
|
|
13,768,101
|
|
||
Energy production
|
3,833,940
|
|
|
—
|
|
||
Total revenues
|
33,202,666
|
|
|
24,490,386
|
|
||
Cost of sales
|
|
|
|
|
|
||
Products
|
8,012,012
|
|
|
7,189,225
|
|
||
Services
|
10,201,732
|
|
|
8,000,483
|
|
||
Energy production
|
2,034,518
|
|
|
—
|
|
||
Total cost of sales
|
20,248,262
|
|
|
15,189,708
|
|
||
Gross profit
|
12,954,404
|
|
|
9,300,678
|
|
||
Operating expenses
|
|
|
|
|
|
||
General and administrative
|
9,520,497
|
|
|
7,994,361
|
|
||
Selling
|
2,271,826
|
|
|
1,636,704
|
|
||
Research and development
|
936,929
|
|
|
667,064
|
|
||
Total operating expenses
|
12,729,252
|
|
|
10,298,129
|
|
||
Income (loss) from operations
|
225,152
|
|
|
(997,451
|
)
|
||
Other income (expense)
|
|
|
|
|
|
||
Interest and other income
|
27,626
|
|
|
11,988
|
|
||
Interest expense
|
(155,082
|
)
|
|
(175,782
|
)
|
||
Total other expense, net
|
(127,456
|
)
|
|
(163,794
|
)
|
||
Income (loss) before income taxes
|
97,696
|
|
|
(1,161,245
|
)
|
||
Income tax provision
|
—
|
|
|
—
|
|
||
Consolidated net income (loss)
|
97,696
|
|
|
(1,161,245
|
)
|
||
(Income) loss attributable to the noncontrolling interest
|
(50,260
|
)
|
|
64,962
|
|
||
Net income (loss) attributable to Tecogen Inc.
|
47,436
|
|
|
(1,096,283
|
)
|
||
Other comprehensive loss-unrealized loss on securities
|
(165,317
|
)
|
|
—
|
|
||
Comprehensive loss
|
$
|
(117,881
|
)
|
|
$
|
(1,096,283
|
)
|
|
|
|
|
||||
Net income (loss) per share - basic
|
$
|
0.00
|
|
|
$
|
(0.06
|
)
|
Net income (loss) per share - diluted
|
$
|
0.00
|
|
|
$
|
(0.06
|
)
|
Weighted average shares outstanding - basic
|
23,171,033
|
|
|
19,295,922
|
|
||
Weighted average shares outstanding - diluted
|
23,342,627
|
|
|
19,295,922
|
|
|
|
Tecogen Inc. Stockholders
|
|
|
|
|
|||||||||||||||||||||
|
|
Common Stock Shares
|
|
Common
Stock $.001 Par Value |
|
Additional
Paid-In Capital |
|
Accumulated Other Comprehensive Loss
|
|
Accumulated
Deficit |
|
Noncontrolling
Interest |
|
Total
|
|||||||||||||
Balance at December 31, 2015
|
|
18,478,990
|
|
|
$
|
18,479
|
|
|
$
|
34,501,640
|
|
|
$
|
—
|
|
|
$
|
(21,682,437
|
)
|
|
$
|
(395,814
|
)
|
|
$
|
12,441,868
|
|
Exercise of warrants
|
|
675,000
|
|
|
675
|
|
|
2,699,325
|
|
|
|
|
—
|
|
|
—
|
|
|
2,700,000
|
|
|||||||
Exercise of stock options
|
|
157,458
|
|
|
158
|
|
|
395,414
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
395,572
|
|
||||||
Acquisition of non-controlling interest in Ilios
|
|
670,464
|
|
|
670
|
|
|
(427,537
|
)
|
|
—
|
|
|
(64,962
|
)
|
|
460,776
|
|
|
(31,053
|
)
|
||||||
Stock-based compensation
|
|
—
|
|
|
—
|
|
|
165,931
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
165,931
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,096,283
|
)
|
|
(64,962
|
)
|
|
(1,161,245
|
)
|
||||||
Balance at December 31, 2016
|
|
19,981,912
|
|
|
$
|
19,982
|
|
|
$
|
37,334,773
|
|
|
$
|
—
|
|
|
$
|
(22,843,682
|
)
|
|
$
|
—
|
|
|
$
|
14,511,073
|
|
Exercise of stock options
|
|
122,043
|
|
|
122
|
|
|
179,796
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
179,918
|
|
||||||
Issuance of common stock in connection with ADGE acquisition, net of costs of $377,246
|
|
4,662,937
|
|
|
4,663
|
|
|
18,477,993
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
18,482,656
|
|
||||||
Consolidation of non-controlling interest in ADGNY
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
453,272
|
|
|
453,272
|
|
||||||
Distributions to non-controlling interest
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(47,921
|
)
|
|
(47,921
|
)
|
||||||
Stock-based compensation
|
|
—
|
|
|
—
|
|
|
183,768
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
183,768
|
|
||||||
Comprehensive income (loss)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(165,317
|
)
|
|
47,436
|
|
|
50,260
|
|
|
(67,621
|
)
|
||||||
Balance at December 31, 2017
|
|
24,766,892
|
|
|
$
|
24,767
|
|
|
$
|
56,176,330
|
|
|
$
|
(165,317
|
)
|
|
$
|
(22,796,246
|
)
|
|
$
|
455,611
|
|
|
$
|
33,695,145
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
2017
|
|
2016
|
||||
|
|
|
|
|
|||
Consolidated net income (loss)
|
$
|
97,696
|
|
|
$
|
(1,161,245
|
)
|
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
|
|
|
|
|
||
Depreciation and amortization, net
|
587,822
|
|
|
264,005
|
|
||
Loss on sale of assets
|
2,909
|
|
|
640
|
|
||
Recovery for losses on accounts receivable
|
(16,600
|
)
|
|
(19,245
|
)
|
||
Provision (recovery) of inventory reserve
|
17,000
|
|
|
(27,000
|
)
|
||
Stock-based compensation
|
183,768
|
|
|
165,931
|
|
||
Non-cash interest expense
|
1,491
|
|
|
49,532
|
|
||
Changes in operating assets and liabilities, net of effects of acquisition:
|
|
|
|
|
|
||
(Increase) decrease in:
|
|
|
|
||||
Short-term investments, restricted
|
—
|
|
|
294,802
|
|
||
Accounts receivable
|
(336,051
|
)
|
|
(3,324,310
|
)
|
||
Unbilled revenue
|
(1,676,409
|
)
|
|
(1,197,254
|
)
|
||
Inventory, net
|
(298,167
|
)
|
|
935,779
|
|
||
Due from related party
|
(325,651
|
)
|
|
916,273
|
|
||
Prepaid expenses and other current assets
|
(47,498
|
)
|
|
(48,771
|
)
|
||
Other non-current assets
|
(32,252
|
)
|
|
—
|
|
||
Increase (decrease) in:
|
|
|
|
|
|
||
Accounts payable
|
1,335,042
|
|
|
55,672
|
|
||
Accrued expenses and other current liabilities
|
(494,095
|
)
|
|
311,398
|
|
||
Deferred revenue
|
375,499
|
|
|
65,937
|
|
||
Interest payable, related party
|
34,240
|
|
|
—
|
|
||
Net cash used in operating activities
|
(591,256
|
)
|
|
(2,717,856
|
)
|
||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
||
Purchases of property and equipment
|
(580,044
|
)
|
|
(139,725
|
)
|
||
Purchases of intangible assets
|
(453,598
|
)
|
|
(119,665
|
)
|
||
Cash acquired in acquisition
|
971,454
|
|
|
—
|
|
||
Cash paid for investment in Ultra Emissions Technologies Ltd
|
—
|
|
|
(2,000,000
|
)
|
||
Return of investment in Ultra Emissions Technologies Ltd
|
2,000,000
|
|
|
—
|
|
||
Payment of stock issuance costs
|
(377,246
|
)
|
|
—
|
|
||
Distributions to noncontrolling interest
|
(47,921
|
)
|
|
—
|
|
||
Net cash provided by (used in) investing activities
|
1,512,645
|
|
|
(2,259,390
|
)
|
||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
||
Payments for debt issuance costs
|
—
|
|
|
(2,034
|
)
|
||
Proceeds on notes payable
|
—
|
|
|
150,000
|
|
||
Payments for share issuance
|
—
|
|
|
(31,053
|
)
|
||
Payments made on loan due to related party
|
(3,150,000
|
)
|
|
—
|
|
||
Proceeds from exercise of stock options
|
179,918
|
|
|
395,572
|
|
||
Proceeds from exercise of warrants
|
—
|
|
|
2,700,000
|
|
||
Net cash provided by (used in) financing activities
|
(2,970,082
|
)
|
|
3,212,485
|
|
||
Change in cash and cash equivalents
|
(2,048,693
|
)
|
|
(1,764,761
|
)
|
||
Cash and cash equivalents, beginning of the year
|
3,721,765
|
|
|
5,486,526
|
|
||
Cash and cash equivalents, end of the year
|
$
|
1,673,072
|
|
|
$
|
3,721,765
|
|
Cash paid for interest
|
$
|
110,979
|
|
|
$
|
126,250
|
|
Exchange of common stock for non-controlling interest in Ilios
|
$
|
—
|
|
|
$
|
330,852
|
|
Issuance of stock to acquire American DG Energy, net
|
$
|
18,482,656
|
|
|
$
|
—
|
|
Issuance of Tecogen stock options in exchange for American DG Energy options
|
$
|
114,896
|
|
|
$
|
—
|
|
|
2017
|
|
2016
|
||||
Net income (loss) attributable to stockholders
|
$
|
47,436
|
|
|
$
|
(1,096,283
|
)
|
Weighted average shares outstanding - Basic
|
23,171,033
|
|
|
19,295,922
|
|
||
Basic income (loss) per share
|
$
|
0.00
|
|
|
$
|
(0.06
|
)
|
Weighted average shares outstanding - Diluted
|
23,342,627
|
|
|
19,295,922
|
|
||
Diluted income (loss) per share
|
$
|
0.00
|
|
|
$
|
(0.06
|
)
|
|
|
|
|
||||
Anti-dilutive shares underlying stock options outstanding
|
441,356
|
|
|
1,117,918
|
|
||
Anti-dilutive convertible debentures
|
—
|
|
|
889,831
|
|
Consideration
|
|
|
||
Tecogen common stock - 4,662,937 shares
|
|
$
|
18,745,007
|
|
Assumed fully vested equity awards
|
|
114,896
|
|
|
|
|
$
|
18,859,903
|
|
|
|
|
||
Recognized amounts of identifiable assets acquired and liabilities assumed
|
|
|
||
Financial assets
|
|
$
|
1,542,137
|
|
Inventory
|
|
75,374
|
|
|
Prepaid and other current assets
|
|
358,628
|
|
|
Property, plant and equipment
|
|
12,186,664
|
|
|
Investment securities
|
|
519,568
|
|
|
Favorable contract asset
|
|
1,561,739
|
|
|
Financial liabilities
|
|
(1,912,859
|
)
|
|
Unfavorable contract liability
|
|
(8,341,922
|
)
|
|
Other liabilities
|
|
(939
|
)
|
|
Total identifiable net assets
|
|
5,988,390
|
|
|
Noncontrolling interest in American DG New York, LLC
|
|
(453,272
|
)
|
|
Goodwill
|
|
13,324,785
|
|
|
|
|
$
|
18,859,903
|
|
|
|
Year ended December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
Total revenues
|
|
$
|
36,232,650
|
|
|
$
|
29,674,375
|
|
Net income (loss)
|
|
113,255
|
|
|
(253,132
|
)
|
||
Basic earnings (loss) per share
|
|
$
|
0.01
|
|
|
$
|
(0.01
|
)
|
Diluted earnings (loss) per share
|
|
$
|
0.01
|
|
|
$
|
(0.01
|
)
|
|
2017
|
|
2016
|
||||
Gross raw materials
|
$
|
5,270,732
|
|
|
$
|
4,658,872
|
|
Less - reserves
|
(283,000
|
)
|
|
(266,000
|
)
|
||
Net raw materials
|
4,987,732
|
|
|
4,392,872
|
|
||
Work-in-process
|
11,852
|
|
|
144,528
|
|
||
Finished goods
|
131,221
|
|
|
236,864
|
|
||
|
$
|
5,130,805
|
|
|
$
|
4,774,264
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
Intangible assets
|
|
Cost
|
|
Accumulated Amortization
|
|
Net
|
|
Cost
|
|
Accumulated Amortization
|
|
Net
|
||||||||||||
Product certifications
|
|
$
|
605,704
|
|
|
$
|
(285,341
|
)
|
|
$
|
320,363
|
|
|
$
|
544,651
|
|
|
$
|
(233,992
|
)
|
|
$
|
310,659
|
|
Patents
|
|
808,323
|
|
|
(154,972
|
)
|
|
653,351
|
|
|
681,155
|
|
|
(123,012
|
)
|
|
558,143
|
|
||||||
Developed technology
|
|
240,000
|
|
|
(76,000
|
)
|
|
164,000
|
|
|
240,000
|
|
|
(60,000
|
)
|
|
180,000
|
|
||||||
Trademarks
|
|
19,540
|
|
|
—
|
|
|
19,540
|
|
|
17,165
|
|
|
—
|
|
|
17,165
|
|
||||||
In Process R&D
|
|
263,001
|
|
|
—
|
|
|
263,001
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Favorable contract asset
|
|
1,561,739
|
|
|
(85,536
|
)
|
|
1,476,203
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
|
$
|
3,498,307
|
|
|
$
|
(601,849
|
)
|
|
$
|
2,896,458
|
|
|
$
|
1,482,971
|
|
|
$
|
(417,004
|
)
|
|
$
|
1,065,967
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Intangible liability
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Unfavorable contract liability
|
|
$
|
8,341,922
|
|
|
$
|
(612,255
|
)
|
|
$
|
7,729,667
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
Non-contract related intangibles
|
|
Contract related intangibles
|
|
Total
|
||||||
2018
|
|
$
|
185,398
|
|
|
$
|
(880,776
|
)
|
|
(695,378
|
)
|
|
2019
|
|
168,748
|
|
|
(781,505
|
)
|
|
(612,757
|
)
|
|||
2020
|
|
162,591
|
|
|
(729,905
|
)
|
|
(567,314
|
)
|
|||
2021
|
|
149,160
|
|
|
(730,478
|
)
|
|
(581,318
|
)
|
|||
2022
|
|
142,083
|
|
|
(696,328
|
)
|
|
(554,245
|
)
|
|||
Thereafter
|
|
592,733
|
|
|
(2,434,472
|
)
|
|
(1,841,739
|
)
|
|||
|
|
$
|
1,400,713
|
|
|
$
|
(6,253,464
|
)
|
|
$
|
(4,852,751
|
)
|
|
Estimated Useful
Life (in Years)
|
|
2017
|
|
2016
|
||||
Energy systems
|
1 - 15 years
|
|
$
|
12,466,642
|
|
|
$
|
—
|
|
Machinery and equipment
|
5 - 7 years
|
|
1,215,951
|
|
|
1,009,893
|
|
||
Furniture and fixtures
|
5 years
|
|
205,320
|
|
|
141,874
|
|
||
Computer software
|
3 - 5 years
|
|
115,253
|
|
|
102,415
|
|
||
Leasehold improvements
|
*
|
|
440,519
|
|
|
437,341
|
|
||
|
|
|
14,443,685
|
|
|
1,691,523
|
|
||
Less - accumulated depreciation and amortization
|
|
|
(2,177,974
|
)
|
|
(1,174,380
|
)
|
||
Net property, plant and equipment
|
|
|
$
|
12,265,711
|
|
|
$
|
517,143
|
|
|
Product and Service
|
|
Energy Production
|
|
Total Company
|
||||||
Balance at December 31, 2016
|
$
|
40,870
|
|
|
$
|
—
|
|
|
$
|
40,870
|
|
Acquisitions
|
—
|
|
|
13,324,785
|
|
|
13,324,785
|
|
|||
Balance at December 31, 2017
|
$
|
40,870
|
|
|
$
|
13,324,785
|
|
|
$
|
13,365,655
|
|
Years Ending December 31,
|
|
Amount
|
||
2018
|
|
$
|
588,021
|
|
2019
|
|
511,382
|
|
|
2020
|
|
513,742
|
|
|
2021
|
|
521,375
|
|
|
2022
|
|
529,115
|
|
|
2023 and thereafter
|
|
671,553
|
|
|
Total
|
|
$
|
3,335,188
|
|
Warranty reserve, December 31, 2015
|
$
|
110,000
|
|
Warranty provision for units sold
|
169,180
|
|
|
Costs of warranty incurred
|
(131,180
|
)
|
|
Warranty reserve, December 31, 2016
|
148,000
|
|
|
Warranty provision for units sold
|
128,100
|
|
|
Costs of warranty incurred
|
(142,600
|
)
|
|
Warranty reserve, December 31, 2017
|
$
|
133,500
|
|
Common Stock Options
|
Number of
Options
|
|
Exercise
Price Per
Share
|
|
Weighted
Average Exercise
Price
|
|
Weighted
Average Remaining
Life
|
|
Aggregate
Intrinsic
Value
|
|||||
Outstanding, December 31, 2016
|
1,117,918
|
|
|
$0.79-$5.39
|
|
$
|
3.10
|
|
|
5.00 years
|
|
$
|
1,415,150
|
|
Granted
|
45,000
|
|
|
$3.22-$3.72
|
|
3.35
|
|
|
|
|
|
|
||
Assumed in merger
|
156,124
|
|
|
$3.15-$30.33
|
|
10.35
|
|
|
|
|
|
|||
Exercised
|
(122,043
|
)
|
|
$0.79-$2.00
|
|
1.47
|
|
|
|
|
|
|
||
Canceled and forfeited
|
(135,447
|
)
|
|
$2.60-30.33
|
|
9.28
|
|
|
|
|
|
|
||
Outstanding, December 31, 2017
|
1,061,552
|
|
|
$0.79-$18.15
|
|
$
|
3.60
|
|
|
4.95 years
|
|
$
|
291,449
|
|
Exercisable, December 31, 2017
|
874,202
|
|
|
|
|
$
|
3.46
|
|
|
|
|
$
|
291,449
|
|
Vested and expected to vest, December 31, 2017
|
1,033,450
|
|
|
|
|
$
|
3.58
|
|
|
|
|
$
|
291,449
|
|
Stock option awards:
|
|
2017
|
|
2016
|
Expected life
|
|
6.25 years
|
|
6.25 years
|
Risk-free interest rate
|
|
1.86%
|
|
1.22%
|
Expected volatility
|
|
23.10%
|
|
32.80%
|
|
Number of
Restricted
Stock
|
|
Weighted
Average
Grant Date
Fair Value
|
|||
Unvested, December 31, 2016
|
77,508
|
|
|
$
|
1.31
|
|
Granted
|
—
|
|
|
—
|
|
|
Vested
|
(34,587
|
)
|
|
1.31
|
|
|
Forfeited
|
—
|
|
|
—
|
|
|
Unvested, December 31, 2017
|
42,921
|
|
|
$
|
1.31
|
|
December 31, 2017
|
|
|
Quoted prices in active markets for identical assets
|
|
Significant other observable inputs
|
|
Significant unobservable inputs
|
|
|
||||||||||
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total gains (losses)
|
||||||||||
Recurring fair value measurements
|
|
|
|
|
|
|
|
|
|
||||||||||
Available-for-sale equity securities
|
|
|
|
|
|
|
|
|
|
||||||||||
EuroSite Power Inc.
|
$
|
354,251
|
|
|
$
|
—
|
|
|
$
|
354,251
|
|
|
$
|
—
|
|
|
$
|
(165,317
|
)
|
Total recurring fair value measurements
|
$
|
354,251
|
|
|
$
|
—
|
|
|
$
|
354,251
|
|
|
$
|
—
|
|
|
$
|
(165,317
|
)
|
|
|
Products and Services
|
|
Energy Production
|
|
Corporate, other and elimination (1)
|
|
Total
|
||||||||
Year ended December 31, 2017
|
|
|
|
|
|
|
|
|
||||||||
Revenue - external customers
|
|
$
|
29,368,726
|
|
|
$
|
3,833,940
|
|
|
$
|
—
|
|
|
$
|
33,202,666
|
|
Intersegment revenue
|
|
750,692
|
|
|
—
|
|
|
(750,692
|
)
|
|
—
|
|
||||
Total revenue
|
|
30,119,418
|
|
|
3,833,940
|
|
|
(750,692
|
)
|
|
33,202,666
|
|
||||
Gross profit
|
|
11,154,982
|
|
|
1,799,422
|
|
|
—
|
|
|
12,954,404
|
|
||||
Identifiable assets
|
|
24,234,505
|
|
|
26,436,571
|
|
|
—
|
|
|
50,671,076
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Year ended December 31, 2016
|
|
|
|
|
|
|
|
|
||||||||
Revenue - external customers
|
|
$
|
24,490,386
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
24,490,386
|
|
Intersegment revenue
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Total revenue
|
|
24,490,386
|
|
|
—
|
|
|
—
|
|
|
24,490,386
|
|
||||
Gross profit
|
|
9,300,678
|
|
|
—
|
|
|
—
|
|
|
9,300,678
|
|
||||
Identifiable assets
|
|
15,674,327
|
|
|
—
|
|
|
8,067,034
|
|
|
23,741,361
|
|
|
|
|
2017
|
|
2016
|
||||
Pre-tax book income (loss)
|
|
$
|
97,697
|
|
|
$
|
(1,161,245
|
)
|
|
Expected tax at 34%
|
|
33,217
|
|
|
(394,823
|
)
|
|||
|
|
|
|
|
|
||||
Permanent differences:
|
|
|
|
|
|||||
|
Machinery & equipment
|
|
10,888
|
|
|
5,459
|
|
||
|
Stock compensation
|
|
(179,084
|
)
|
|
—
|
|
||
|
Non-deductible interest
|
|
10,788
|
|
|
—
|
|
||
|
Other
|
|
26
|
|
|
754
|
|
||
|
|
|
|
|
|
||||
State taxes:
|
|
|
|
|
|||||
|
Current
|
|
—
|
|
|
—
|
|
||
|
Deferred
|
|
(24,960
|
)
|
|
(96,754
|
)
|
||
|
|
|
|
|
|
||||
Other items:
|
|
|
|
|
|||||
|
Federal research and development credits
|
|
(33,406
|
)
|
|
(15,996
|
)
|
||
|
Change in valuation allowance
|
|
277,000
|
|
|
96,754
|
|
||
|
Deferred tax past year true-up's
|
|
191,355
|
|
|
(8,584
|
)
|
||
|
ADGE deferred tax assets and liabilities at purchase
|
|
(3,702,013
|
)
|
|
—
|
|
||
|
ADGE other post-closing adjustments
|
|
(1,330,665
|
)
|
|
—
|
|
||
|
Change in statutory tax rate for deferred tax assets-Federal
|
|
4,914,329
|
|
|
—
|
|
||
|
Change in statutory tax rate for deferred tax assets-State
|
|
(167,475
|
)
|
|
—
|
|
||
Unbenefitted operating losses
|
|
—
|
|
|
413,190
|
|
|||
Income tax provision
|
|
$
|
—
|
|
|
$
|
—
|
|
|
2017
|
|
2016
|
||||
Net operating loss carryforwards
|
$
|
7,429,000
|
|
|
$
|
6,885,000
|
|
R&D and ITC credit carryforwards
|
203,000
|
|
|
145,000
|
|
||
Accrued expenses and other
|
879,000
|
|
|
1,740,000
|
|
||
Accounts receivable
|
6,000
|
|
|
11,000
|
|
||
Inventory
|
73,000
|
|
|
208,000
|
|
||
Property, plant and equipment
|
801,000
|
|
|
125,000
|
|
||
Deferred tax assets
|
9,391,000
|
|
|
9,114,000
|
|
||
Valuation allowance
|
(9,391,000
|
)
|
|
(9,114,000
|
)
|
||
Deferred tax assets, net
|
$
|
—
|
|
|
$
|
—
|
|
1.
|
Purpose of the Plan.
This 2006 Stock Incentive Plan (the "Plan"), as amended to date, is intended to provide incentives (a) to the officers and employees of Tecogen Inc., a Delaware corporation (the "Company"), and any parent or subsidiary of the Company, by providing such officers and employees with opportunities to purchase stock in the Company pursuant to options granted hereunder which qualify as "incentive stock options" under Section 422(b) of the Internal Revenue Code of 1986, as amended (the "Code") ("ISO" or "ISOs"); (b) to directors, officers, employees, consultants and advisors of the Company and any present or future parent, subsidiary or affiliate of the Company (hereinafter collectively “Related Corporations”) by providing them with opportunities to purchase stock in the Company pursuant to options granted hereunder which do not qualify as ISOs ("Non-Qualified Option" or "Non-Qualified Options"); (c) to directors, officers, employees, consultants and advisors of the Company and Related Corporations by providing them with opportunities to receive awards of stock in the Company whether such stock awards are in the form of bonus shares, deferred stock awards, or of performance share awards ("Awards"); and (d) to directors, officers, employees, consultants and advisors of the Company and Related Corporations by providing them with opportunities to make direct purchases of restricted stock in the Company ("Restricted Stock Purchases"). Both ISOs and Non-Qualified Options are referred to hereafter individually as an "Option" and collectively as "Options". Options, Awards and authorizations to make Restricted Stock Purchases are referred to hereafter individually as a “Stock Right” and collectively as "Stock Rights". As used herein, the terms "parent" and "subsidiary" mean “parent corporation” and "subsidiary corporation", respectively, as those terms are defined in Section 424 of the Code.
|
2.
|
Administration of the Plan
|
a.
|
Board or Committee Administration.
This Plan shall be administered by the Board of Directors of the Company (the “Board”). The Board may appoint a Compensation Committee or Human Resources Committee (as the case may be, the “Committee”) of two (2) or more of its members to administer this Plan and to grant Stock Rights hereunder, provided such Committee is delegated such powers in accordance with applicable state law. (All references in this Plan to the “Committee” shall mean the Board if no such Compensation Committee or Stock Incentive Plan Committee has been so appointed). If the Company or any Related Corporation registers any class of any equity security pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Plan shall be administered in accordance with the applicable rules set forth in Rule 16b-3 or any successor provisions of the Exchange Act (“Rule 16b-3”). From and after the date the Company becomes subject to Section 162(m) of the Code with respect to compensation earned under this Plan, each member of the Committee shall also be an “outside director” within the meaning of Section 162(m) of the Code and the regulations promulgated thereunder.
|
b.
|
Authority of Board or Committee.
Subject to the terms of this Plan, the Committee shall have the authority to: (i) determine the employees of the Company and any Related Corporation (from among the class of employees eligible under paragraph 3 to receive ISOs) to whom ISOs may be granted, and to determine (from among the class of individuals and entities eligible under paragraph 3 to receive Non-Qualified Options and Awards and to make Restricted Stock Purchases) to whom Non-Qualified Options, Awards and authorizations to make Restricted Stock Purchases may be granted; (ii) determine the time or times at which Options or Awards may be granted or Restricted Stock Purchases made; (iii) determine the exercise price of shares subject to each Option, which price shall not be less than the minimum price specified in paragraph 6, and the purchase price of shares subject to each Restricted Stock Purchase; (iv) determine whether each Option granted shall be an ISO or a Non-Qualified Option; (v) determine (subject to paragraph 8) the time or times when or what conditions must be satisfied before each Option shall become exercisable and the duration of the exercise period; (vi) determine whether restrictions such as transfer restrictions, repurchase options and “drag along” rights and rights of first refusal are to be imposed on shares subject to Options, Awards and Restricted Stock Purchases and the nature of such restrictions, if any; (vii) impose such other terms and conditions with respect to capital stock issued pursuant to Stock Rights not inconsistent with the terms of this Plan as it deems necessary or desirable; and (viii) interpret the Plan and prescribe and rescind rules and regulations relating to it.
|
c.
|
Delegation of Authority to Grant Awards to Officer.
Without limiting the foregoing, the Board, in its discretion, may also delegate to a single officer of the Company who is a member of the Board (to the extent consistent with state law) all or part of the Board’s or Committee’s authority and duties with respect to the granting of Stock Rights to individuals who are not subject to the reporting and other provisions of Section 16 of the Exchange Act or “covered employees” within the meaning of Section 162(m) of the Code, subject to such limitations as the Board or the Committee deems appropriate, including without limitation as to the amount of Stock Rights that may be granted during the period of delegation, and guidelines as to the determination of the exercise price of any Option, the purchase price of other Stock Rights and the setting of vesting schedules or criteria. Such officer (the “Delegated Officer”) shall act as a one member committee of the Board, and shall in any event be subject to the same limitations as are applicable to the Committee. References to the Committee in this Plan shall also include the Delegated Officer, but only to the extent consistent with the authorities and duties delegated to the Delegated Officer by the Board. The Board may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Delegated Officer that were consistent with the terms of this Plan.
|
d.
|
Committee Actions.
The Committee may select one of its members as its chairman and shall hold meetings at such time and places as it may determine. Acts by a majority of the Committee, acting at a meeting (whether held in person or by teleconference), or acts reduced to or approved in writing by all of the members of the Committee, shall be the valid acts of the Committee. From time to time the Board may increase the size of the Committee and appoint additional members thereof, remove members (with or without cause) and appoint new members in substitution therefor, fill vacancies however caused, or remove all members of the Committee and thereafter directly administer this Plan, subject to compliance with paragraph 2(a).
|
e.
|
Grant of Stock Rights to Board Members.
Stock Rights may be granted to members of the Board, subject to compliance with Rule 16b-3 when required by paragraph 2(a). All grants of Stock Rights to members of the Board shall in all respects be made in accordance with the provisions of this Plan applicable to other eligible persons.
|
3.
|
Eligible Employees and Others.
ISOs may be granted to any employee of the Company or any parent or subsidiary of the Company. Those officers and directors of the Company who are not employees of the Company or any parent or subsidiary of the Company may not be granted ISOs under this Plan. Non-Qualified Options, Awards and authorizations to make Restricted Stock Purchases may be granted to any employee, officer or director (whether or not also an employee) of or consultant or advisor to the Company or any Related Corporation. The Committee may take into consideration a recipient's individual circumstances in determining whether to grant a Stock Right. Granting a Stock Right to any individual or entity shall neither entitle that individual or entity to, nor disqualify him or her from, participation in any other grant of Stock Rights.
|
4.
|
Stock.
The stock subject to Stock Rights shall be the authorized but unissued shares of Common Stock of the Company (the “Common Stock”), or shares of Common Stock reacquired by the Company in any manner. The aggregate number of shares of Common Stock which may be issued pursuant to this Plan is 3,838,750 subject to adjustment as provided in paragraph 13 or amendment as provided in Section 15. Any such shares may be issued pursuant to the exercise of Stock Rights, so long as the aggregate number of shares so issued does not exceed the number of such shares authorized under this paragraph 4.
|
5.
|
Granting of Stock Rights.
Stock Rights may be granted under this Plan at any time on or after January 1, 2006 and prior to January 1, 2026. The date of grant of a Stock Right under this Plan will be the date specified by the Committee at the time it grants the Stock Right or such date that is specified in the instrument or agreement evidencing such Stock Right; provided, however, that such date shall not be prior to the date on which the Committee acts to approve the grant and that with respect to an ISO grant such date shall not be earlier than the date of commencement of employment of the employee granted the ISO. The Committee shall have the right, with the consent of the optionee, to convert an ISO granted under this Plan to a Non-Qualified Option pursuant to paragraph 17.
|
6.
|
Minimum Option Price; ISO Limitations
|
a.
|
Price for ISOs.
The exercise price per share specified in the agreement relating to each ISO granted under this Plan shall not be less than the fair market value per share of Common Stock on the date of such grant. In the case of an ISO to be granted to an employee owning stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, the price per share specified in the agreement relating to such ISO shall not be less than one hundred ten percent (110%) of the fair market value per share of Common Stock on the date of grant.
|
b.
|
$100,000 Annual Limitation on ISOs.
Each eligible employee may be granted ISOs only to the extent that, in the aggregate under this Plan and all other incentive stock option plans of the Company and any parent or subsidiary of the Company, such ISOs do not become exercisable for the first time by such employee during any calendar year in a manner which would entitle the employee to purchase more than $100,000 in fair market value (determined at the time the ISOs were granted) of Common Stock in that year. Any Options granted to an employee in excess of such amount will be granted as Non-Qualified Options.
|
c.
|
Determination of Fair Market Value.
If, at the time an Option is granted under the Plan, the Common Stock is publicly traded, "fair market value" shall be determined as of the last business day for which the prices or quotes discussed in this sentence are available prior to the date such Option is granted and shall mean (i) the average (on that date) of the high and low prices of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (ii) the last reported sale price (on that date) of the Common Stock on the NASDAQ National Market List, if the Common Stock is not then traded on a national securities exchange; or (iii) the closing bid price (or average of bid prices) last quoted (on that date) by an established quotation service for over-the-counter securities, if the Common Stock is not then traded on a national securities exchange and is not reported on the NASDAQ National Market List. However, if the Common Stock is not publicly traded at the time an Option is granted under the Plan, "fair market value" shall be deemed to be the fair value of the Common Stock as determined by the Committee after taking into consideration all factors in good faith it deems appropriate, including, without limitation, recent sale and offer prices of the Common Stock in private transactions negotiated at arm's length, if any.
|
7.
|
Option Duration.
Subject to earlier termination as provided in paragraphs 9, 10, and 13(b), each Option shall expire on the date specified by, or shall have such duration as may be specified by, the Committee and set forth in the original stock option agreement granting such Option, but not more than ten years from the date of grant. Notwithstanding the foregoing, in the case of ISOs granted to an employee owning stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, such ISOs shall expire not more than five years from the date of grant. Non-Qualified Options shall expire on the date specified in the agreement granting such Non-Qualified Options, subject to extension as determined by the Committee. ISOs, or any part thereof, that have been converted into Non-Qualified Options may be extended as provided in paragraph 17.
|
8.
|
Exercise of Options.
Subject to the provisions of paragraphs 9 through 13, each Option granted under the Plan shall be exercisable as follows:
|
a.
|
Vesting.
As set forth in paragraph 2(b), and subject to paragraphs 9 and 10 with respect to ISOs, the Committee shall determine the time or times when or what conditions must be satisfied before each Option shall become exercisable and the duration of the exercise period. The Committee may also specify such other conditions precedent as it deems appropriate to the exercise of an Option.
|
b.
|
Full Vesting of Installments.
Once an installment becomes exercisable it shall remain exercisable until expiration or termination of the Option, unless otherwise specified by the Committee.
|
c.
|
Partial Exercise.
Each Option or installment may be exercised at any time or from time to time, in whole or in part, for up to the total number of shares with respect to which it is then exercisable, provided that the Committee may specify a certain minimum number or percentage of the shares issuable upon exercise of any Option that must be purchased upon any exercise.
|
d.
|
Acceleration of Vesting.
The Committee shall have the right to accelerate the date of exercise of any installment of any Option, despite the fact that such acceleration may (i) cause the application of Sections 280G and 4999 of the Code if a Change in Control Event, as defined below in paragraph 13(b), occurs, or (ii) disqualify all or part of the Option as an ISO.
|
9.
|
Termination of Employment.
Subject to the provisions of paragraph 13(b), if an ISO optionee ceases to be employed by the Company and all Related Corporations other than by reason of death or disability as defined in paragraph 10, no further installments of his or her ISOs shall become exercisable following the date of such cessation of employment, and his or her ISOs shall terminate after the passage of ninety (90) days from the date of termination of his or her employment, but in no event later than on their specified expiration dates, except to the extent that such ISOs (or unexercised installments thereof) have been converted into Non-Qualified Options pursuant to paragraph 17. Nothing in this Plan shall be deemed to give any grantee of any Stock Right the right to be retained in employment or other service by the Company or any Related Corporation for any period of time.
|
10.
|
Death; Disability
|
a.
|
Death.
If an ISO optionee ceases to be employed by the Company and all Related Corporations by reason of his or her death, or if the employee dies within the thirty (30) day period after the employee ceases to be employed by the Company and all Related Corporations, any ISO of his or hers may be exercised, to the extent of the number of shares with respect to which he or she could have exercised it on the date of his or her death, by his or her estate, personal representative or beneficiary who has acquired the ISO by will or by the laws of descent and distribution, at any time prior to the earlier of the specified expiration date of the ISO or one (1) year from the date of such optionee's death.
|
b.
|
Disability.
If an ISO optionee ceases to be employed by the Company and all Related Corporations by reason of his or her disability, he or she shall have the right to exercise any ISO held by the optionee on the date of termination of employment, to the extent of the number of shares with respect to which he or she could have exercised it on that date, at any time prior to the earlier of the specified expiration date of the ISO or one (1) year from the date of the termination of the optionee's employment. For the purposes of the Plan, the term "disability" shall mean "permanent and total disability" as defined in Section 22(e)(3) of the Code or successor statute.
|
11.
|
Assignability.
Except for Non-Qualified Options which may be transferred for estate planning purposes to the extent provided in the instrument or agreement granting such Non-Qualified Options, no Stock Right shall be assignable or transferable by the grantee except by will or by the laws of descent and distribution, and during the lifetime of the grantee each Stock Right shall be exercisable only by the optionee. No Stock Right, and no right to exercise any portion thereof, shall be subject to execution, attachment, or similar process, assignment, or any other alienation or hypothecation. Upon any attempt so to transfer, assign, pledge, hypothecate, or otherwise dispose of any Stock Right, or of any right or privilege conferred thereby, contrary to the provisions thereof or hereof or upon the levy of any attachment or similar process upon any Stock Right, right or privilege, such Stock Right and such rights and privileges shall immediately become null and void. The foregoing shall not be construed to restrict the ability to assign or transfer shares of Common Stock issued upon the exercise or award of a Stock Right to the extent that the instrument or agreement granting such Stock Right permits such assignment or transfer.
|
12.
|
Terms and Conditions of Stock Rights.
Stock Rights shall be evidenced by instruments (which need not be identical) in such forms as the Committee may from time to time approve. Such instruments shall conform to the terms and conditions set forth in paragraphs 6 through 11 hereof to the extent applicable and may contain such other provisions as the Committee deems advisable which are not inconsistent with this Plan. Without limiting the foregoing, such provisions may include transfer restrictions, rights of refusal, vesting provisions, repurchase rights, lock-up provisions and drag-along rights with respect to shares of Common Stock issuable upon exercise of Stock Rights, and such other restrictions applicable to shares of Common Stock as the Committee may deem appropriate. In granting any Non-Qualified Option, the Committee may specify that such Non-Qualified Option shall be subject to the restrictions set forth herein with respect to ISOs, or to such other termination, cancellation or other provisions as the Committee may determine. The Committee may from time to time confer authority and responsibility on one or more of its own members and/or one or more officers of the Company to execute and deliver such instruments. The proper officers of the Company are authorized and directed to take any and all action necessary or advisable from time to time to carry out the terms of such instruments.
|
13.
|
Adjustments.
Upon the occurrence of any of the following events, an optionee's rights with respect to Options granted to the optionee hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in the written agreement between the optionee and the Company relating to such Option:
|
a.
|
Stock Dividends and Stock Splits.
If the shares of Common Stock subject to Options granted under this Plan shall be subdivided or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, the number of shares of Common Stock deliverable upon the exercise of Options shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or stock dividend.
|
b.
|
Acquisitions and Change in Control Events.
If the Company is to be subject to or engage in (x) a merger (or reverse merger), consolidation, or other similar event affecting the Company in which outstanding shares of Common Stock are exchanged for cash, securities, and/or other property of another entity, or (y) the sale or lease of all or substantially all of the Company’s assets to another person or entity (any such event in such clauses (x) and (y) an “Acquisition”), the Committee or the Board shall (i) provide that the entity that survives the Acquisition or purchases or leases the Company’s assets in the Acquisition or any affiliate of such entity (the “Surviving Entity”) shall assume the Options granted pursuant to this Plan or substitute options to purchase securities of the Surviving Entity (or an affiliate thereof) on an equitable basis, (ii) upon written notice to the optionees, provide that all Options will become exercisable in full subject to the consummation of the Acquisition as of a specified time prior to the Acquisition and will terminate immediately prior to the consummation of such Acquisition or within a specified period of time after the Acquisition, and will not be exercisable after such termination, or (iii) in the event of an Acquisition under the terms of which holders of Common Stock will receive upon consummation thereof an amount of cash, securities and/or other property for each share of Common Stock surrendered pursuant to such Acquisition (the amount of cash plus the fair market value reasonably determined by the Committee of any securities and/or other property received by holders of Common Stock in exchange for each share of Common Stock shall be the “Acquisition Price”), provide that all outstanding Options shall terminate upon consummation of such Acquisition and that each optionee shall receive, in exchange for all vested shares of Common Stock under such Option on the date of the Acquisition, a payment in cash or in kind having a fair market value reasonably determined by the Committee or the board of directors of the Surviving Entity equal to the amount (if any) by which (A) the Acquisition Price multiplied by the number of such vested shares of Common Stock exceeds (B) the aggregate exercise price of such shares. If the Committee chooses under clause (iii) in the preceding sentence that all outstanding Options shall terminate upon consummation of an Acquisition and that each optionee shall receive a payment for the optionee’s vested shares, with respect to any optionee whose stock option agreement specifies that no shares are vested until the first anniversary of the commencement of the optionee’s employment, if the consummation of the Acquisition occurs prior to such first anniversary, then the number of vested shares under such Option shall be deemed to be equal to the product of (x) the number of shares of stock subject to the Option that otherwise would vest on the first anniversary and (y) the quotient obtained by dividing the number of days the optionee was employed by the Company, by 365. For purposes hereof, an Option shall be considered to be assumed or substituted “on an equitable basis” (without limiting other ways in which an Option may be assumed or substituted on an equitable basis hereunder) if, following consummation of the Acquisition, the assumed or substituted option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Acquisition, the consideration received as a result of the Acquisition by the holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Acquisition (and if holders of Common Stock were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a result of the Acquisition Event is not solely Common Stock of the Surviving Entity (or an affiliate thereof), the Company may, with the consent of the Surviving Entity, provide for the consideration to be received upon the exercise of each share of Common Stock subject to the Option to consist solely of Common Stock of the Surviving Entity (or an affiliate thereof) having a fair market value as reasonably determined by the Committee or the board of directors of the Surviving Entity equal to the Acquisition Price.
|
c.
|
Recapitalization or Reorganization.
If a recapitalization or reorganization of the Company (other than a transaction described in subparagraph (b) above) occurs, pursuant to which securities of the Company or another entity are issued with respect to the outstanding shares of Common Stock, an optionee, upon exercising an Option, shall be entitled to receive for the purchase price paid upon such exercise the securities he or she would have received if he or she had exercised his or her Option prior to such recapitalization or reorganization and had been the owner of the Common Stock receivable upon such exercise at such time.
|
d.
|
Modification of ISOs.
Notwithstanding the foregoing, any adjustments made pursuant to the foregoing subparagraphs (a), (b) or (c) with respect to ISOs shall be made only after the Committee, after consulting with counsel for the Company, determines whether such adjustments would constitute a "modification" of such ISOs (as that term is defined in Section 424 of the Code or any successor thereto) or would cause any adverse tax consequences for the holders of such ISOs. If the Committee determines that such adjustments made with respect to ISOs would constitute a modification of such ISOs, it may refrain from making such adjustments.
|
e.
|
Issuances of Securities and Non-Stock Dividends.
Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, of the Company shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Options. No adjustments shall be made for dividends paid in cash or in property other than securities of the Company (and, in the case of securities of the Company, such adjustments shall be made pursuant to the foregoing subparagraph (a)).
|
f.
|
Fractional Shares.
No fractional shares shall be issued under this Plan, and the optionee shall receive from the Company cash in lieu of such fractional shares.
|
g.
|
Adjustments.
Upon the happening of any of the foregoing events described in subparagraphs (a), (b) or (c) above, the class and aggregate number of shares set forth in paragraph 4 hereof that are subject to Stock Rights which previously have been or subsequently may be granted under this Plan shall also be appropriately adjusted to reflect the events described in such subparagraphs. The Committee or the board of directors of the Surviving Entity (the “Successor Board”), as applicable, shall determine the specific adjustments to be made under this paragraph 13 and its determination shall be conclusive.
|
14.
|
Means of Exercising Options
. An Option (or any part or installment thereof) shall be exercised by giving written notice to the Company at its principal office address. Such notice shall identify the Option being exercised and specify the number of shares as to which such Option is being exercised, accompanied by full payment of the purchase price therefor either (a) in United States dollars in cash or by check, or (b) at the discretion of the Committee, by delivery of an irrevocable and unconditional undertaking, satisfactory in form and substance to the Company, by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, or delivery to the Company of a copy of irrevocable and unconditional instructions, satisfactory in form and substance to the Company, to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price, or (c) at the discretion of the Committee, by delivery of the grantee's personal recourse note bearing interest payable not less than annually at no less than 100% of the applicable Federal rate, as defined in Section 1274(d) of the Code, or (d) at the discretion of the Committee, by any combination of (a), (b) and (c) above. The holder of an Option shall not have the rights of a stockholder with respect to the shares covered by his or her Option until the date of issuance of a stock certificate to the optionee for the shares subject to the Option. Except as expressly provided above in paragraph 13 with respect to changes in capitalization and stock dividends, no adjustment shall be made for dividends or similar rights for which the record date is before the date such stock certificate is issued.
|
15.
|
Term and Amendment of Plan
. This Plan was originally adopted by the stockholders of the Company and the Board on December 22, 2005. This Plan shall expire on January 1, 2026 (except as to Options outstanding on that date). Subject to the provisions of paragraph 5 above, Options may be granted under this Plan prior to the date of stockholder approval of this Plan. The Board may terminate or amend this Plan in any respect at any time, except that (a) the total number of shares that may be issued under this Plan may not be increased without stockholder approval (except by adjustment pursuant to paragraph 13); (b) the provisions of paragraph 3 regarding eligibility for grants of ISOs may not be modified; (c) the provisions of paragraph 6(b) regarding the exercise price at which shares may be offered pursuant to ISOs may not be modified (except by adjustment pursuant to paragraph 13); and (d) the expiration date of this Plan may not be extended without the approval of the stockholders obtained within 12 months before or after the Board adopts a resolution authorizing any of the foregoing actions.
|
16.
|
Section 162(m).
Notwithstanding anything in this Plan to the contrary, no Stock Right shall become exercisable, vested or realizable if such Stock Right is granted to an employee that is a “covered employee” as defined in Section 162(m) of the Code and the Committee has determined that such Stock Right should be structured so that it is not “applicable employee remuneration” under such Section 162(m) unless and until the terms of this Plan, including any amendment hereto, have been approved by the Company’s stockholders in the manner and to the extent required under such Section 162(m).
|
17.
|
Amendment of Stock Rights.
The Board or Committee may amend, modify or terminate any outstanding Stock Rights including, but not limited to, substituting therefor another Stock Right of the same or a different type, changing the date of exercise or realization, and converting an ISO to a Non-Qualified Option, provided, that, except as otherwise provided in paragraphs 9 or 10, the grantee's consent to such action shall be required unless the Board or Committee determines that the action, taking into account any related action, would not materially and adversely affect the grantee.
|
18.
|
Application of Funds.
The proceeds received by the Company from the sale of shares pursuant to Stock Rights issued or granted under this Plan shall be used for general corporate purposes.
|
19.
|
Governmental Regulation.
The Company's obligation to sell and deliver shares of the Common Stock under this Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares.
|
20.
|
Withholding of Additional Income Taxes.
Upon the exercise of a Non-Qualified Option, the making of a Restricted Purchase of Common Stock for less than its fair market value, the granting of an Award, the making of a Disqualifying Disposition (as defined in paragraph 21) or the vesting of restricted Common Stock acquired on the exercise of a Stock Right hereunder, the Company, in accordance with Section 3402(a) of the Code, may require the optionee or purchaser to pay additional withholding taxes in respect of the amount that is considered compensation includible in such person's gross income. The Committee in its discretion may condition (i) the exercise of an Option, (ii) the making of a Restricted Stock Purchase of Common Stock for less than its fair market value, or (iii) the granting of an award, or (iv) the vesting of restricted Common Stock acquired by exercising a Stock Right, on the grantee's payment of such additional withholding taxes.
|
21.
|
Notice to Company of Disqualifying Disposition.
Each employee who receives an ISO must agree to notify the Company in writing immediately after the employee makes a Disqualifying Disposition of any Common Stock acquired pursuant to the exercise of an ISO. A “Disqualifying Disposition” is any disposition (including any sale) of such Common Stock before the later of
|
a.
|
two years after the date the employee was granted the ISO, or
|
b.
|
one year after the date the employee acquired Common Stock by exercising the ISO. If the employee has died before such stock is sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter.
|
22.
|
Governing Law; Construction.
The validity and construction of this Plan and the instruments evidencing Stock Rights shall be governed by the laws of the State of Delaware.
|
|
||
|
|
|
Subsidiaries
|
|
Jurisdiction
|
|
|
|
TTcogen LLC
|
|
Delaware
|
American DG Energy Inc.
|
|
Delaware
|
Ultera Technologies Inc.
|
|
Delaware
|
American DG New York, LLC
|
|
Delaware
|
1.
|
I have reviewed this Annual Report on Form 10-K of Tecogen Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
1.
|
I have reviewed this Annual Report on Form 10-K of Tecogen Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
1.
|
I have reviewed this Annual Report on Form 10-K of Tecogen Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
1.
|
The Annual Report on Form 10-K of the Company for the year ended
December 31, 2017
, or the Report, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|